NCT04929080 - The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC | Biotech Hunter

Enrollment

149

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

March 6, 2023

Study Completion Date

March 6, 2023

Conditions

Head and Neck Squamous Cell CarcinomNasopharyngeal Carcinoma

Interventions

BIOLOGICAL

JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

BIOLOGICAL

JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

BIOLOGICAL

JS001 and JS004

Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001

Trial Locations (1)

Sichuan Cancer Hospital, Chengdu

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER